GENEVA–(BUSINESS WIRE)–Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
Author: Business Wire
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
GENEVA–(BUSINESS WIRE)–Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
Pair Eyewear Implements Veero® EyeSize Fit-Optimization Software to Deliver Precision Fit to Online Shoppers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Veero, the SaaS platform solving online eyewear fit, today announced Pair Eyewear, the direct-to-consumer brand reimagining glasses as a form of self expression, has launched Veero’s EyeSize solution. The relationship…
Sightview Appoints Jeff Macomber as Chief Technology Officer
DURHAM, N.C.–(BUSINESS WIRE)– #EHR–As chief technology officer, Jeff Macomber will modernize and unify Sightview’s offerings for optometrists, ophthalmologists and opticians.
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the t…
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
AHMEDABAD, India–(BUSINESS WIRE)–Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APA…
Bausch + Lomb Announces Board Changes
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination …
jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzeretcel) for the treatment of retinitis pigmentosa (RP). …
Saudi Arabia OTC Artificial Tears Market Report 2025-2033 | Vision 2030 Boosts Retail and Online Channels, Non-Prescription Eye Care Boom Fuels Expansion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Saudi Arabia OTC Artificial Tears Market – Demand & Forecast 2025-2033” report has been added to ResearchAndMarkets.com’s offering. Saudi Arabia OTC Artificial Tears Market is expected to reach US$ 79.09 million by 203…
Saudi Arabia Vision Care Market Forecast 2025-2033 | Aging Population, Rising Eye Disorders, Screen Exposure, and Expanding Access to Advanced Eye Care Propel Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Saudi Arabia Vision Care Market Forecast 2025-2033” report has been added to ResearchAndMarkets.com’s offering. Saudi Arabia Vision Care Market is expected to reach US$ 1.29 billion by 2033 from US$ 899.58 million in 2024,…
Bausch + Lomb to Participate in Upcoming Investor Conferences
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two invest…
Avista Therapeutics and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership
PITTSBURGH & COLUMBUS, Ohio–(BUSINESS WIRE)–Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, …
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
First FDA-Approved Treatment for MacTel Performed
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the first commercial manufacturing, shipment, and surgical procedure for EN…
Warby Parker Announces Second Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. “It has been a bu…
STAAR Surgical Reports Second Quarter 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June…
PolyActiva Announces First Patient Enrolled in US Phase 2b Clinical Trial of its Ocular Micro Implant for Glaucoma and Ocular Hypertension
FORT WORTH, Texas & MELBOURNE, Australia–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that the first U.S. p…
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that To…